Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) have been given an average recommendation of “Buy” by the ten brokerages that are currently covering the stock, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy rating and three have issued a strong buy rating on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $17.56.

A number of research firms have recently commented on TRVI. Raymond James raised shares of Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their price target for the company from $9.00 to $29.00 in a research report on Monday, March 10th. HC Wainwright reissued a “buy” rating and set a $12.50 target price on shares of Trevi Therapeutics in a research report on Wednesday, March 19th. Oppenheimer upped their price target on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the company an “outperform” rating in a report on Tuesday, March 11th. D. Boral Capital reiterated a “buy” rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Finally, Needham & Company LLC restated a “buy” rating and set a $24.00 target price on shares of Trevi Therapeutics in a research note on Tuesday, April 8th.

Insider Transactions at Trevi Therapeutics

In other news, CEO Jennifer L. Good sold 5,263 shares of the firm’s stock in a transaction that occurred on Friday, March 21st. The shares were sold at an average price of $6.58, for a total transaction of $34,630.54. Following the completion of the sale, the chief executive officer now owns 213,313 shares of the company’s stock, valued at approximately $1,403,599.54. This trade represents a 2.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Farrell Simon sold 81,313 shares of the firm’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $6.75, for a total value of $548,862.75. Following the sale, the insider now directly owns 76,900 shares of the company’s stock, valued at $519,075. This represents a 51.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. 24.37% of the stock is owned by insiders.

Hedge Funds Weigh In On Trevi Therapeutics

A number of institutional investors have recently modified their holdings of TRVI. Summit Investment Advisors Inc. lifted its position in Trevi Therapeutics by 84.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company’s stock valued at $26,000 after purchasing an additional 2,894 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Trevi Therapeutics during the fourth quarter worth approximately $49,000. Squarepoint Ops LLC acquired a new position in Trevi Therapeutics in the fourth quarter valued at approximately $58,000. Two Sigma Advisers LP bought a new position in Trevi Therapeutics in the fourth quarter valued at approximately $66,000. Finally, China Universal Asset Management Co. Ltd. bought a new position in Trevi Therapeutics in the fourth quarter valued at approximately $67,000. 95.76% of the stock is owned by institutional investors.

Trevi Therapeutics Stock Performance

Trevi Therapeutics stock opened at $6.45 on Wednesday. Trevi Therapeutics has a twelve month low of $2.30 and a twelve month high of $7.39. The firm has a market cap of $644.31 million, a PE ratio of -14.66 and a beta of 0.62. The firm’s 50 day moving average price is $6.24 and its two-hundred day moving average price is $4.58.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.04. Equities analysts anticipate that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.